ArticleSchizophrenia research2013
Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011.
Article in Schizophrenia research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Family-focused therapy for individuals at high clinical risk for psychosis: A confirmatory efficacy trial.Early intervention in psychiatry · 2022Trial
- Right hippocampal volume and attenuated psychotic symptoms distinguish subgroups of youth with common patterns of temporoparietal effective connectivity.Brain structure & function · 2026Article
- Prediction of antipsychotic medication inception in antipsychotic-naive youth at clinical high risk for psychosis.Psychological medicine · 2025Observational
- Correlations between Negative Symptoms and Cognitive Deficits in Individuals at First Psychotic Episode or at High Risk of Psychosis: A Systematic Review.Journal of clinical medicine · 2023Review
- Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals.European archives of psychiatry and clinical neuroscience · 2022Article
- Prediction and Prevention in the Clinical High-Risk for Psychosis Paradigm: A Review of the Current Status and Recommendations for Future Directions of Inquiry.Frontiers in psychiatry · 2021Review
- Predictive validity of conversion from the clinical high risk syndrome to frank psychosis.Schizophrenia research · 2020Article
- Treatment History of Youth At-Risk for Serious Mental Illness.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2019Article
- The relation of atypical antipsychotic use and stress with weight in individuals at clinical high risk for psychosis.Stress and health : journal of the International Society for the Investigation of Stress · 2018Article
- Age-related trajectories of social cognition in youth at clinical high risk for psychosis: An exploratory study.Schizophrenia research · 2018Article
- Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups.Schizophrenia bulletin · 2018Article
- A critique of the "ultra-high risk" and "transition" paradigm.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2017Article
- Insights into psychosis risk from leukocyte microRNA expression.Translational psychiatry · 2016Article
- Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study.JAMA psychiatry · 2016Article
- Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis.European child & adolescent psychiatry · 2016Article
- Toward earlier identification and preventative intervention in schizophrenia: evidence from the London Child Health and Development Study.Social psychiatry and psychiatric epidemiology · 2016Review
- Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis.Schizophrenia bulletin · 2015Article
- Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk.JAMA psychiatry · 2015Article
- Demographic correlates of attenuated positive psychotic symptoms.Schizophrenia research · 2015Article
- Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project.Schizophrenia bulletin · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundAntipsychotic medication use rates have generally been rising among youth with psychiatric disorders, but little is known about use rates of antipsychotics or other psychotropic medications in patients at high risk for psychosis.
methodBaseline psychotropic medication use rates were compared in two research cohorts of patients at high risk for psychosis that enrolled between 1998-2005 (n=391) and 2008-2011 (n=346). Treatment durations and antipsychotic doses were described for cohort 2.
resultsMedian age was 17years in cohort 1 and 18years in cohort 2. The rate of prescription of any psychotropic at baseline was roughly 40% for each cohort. Antipsychotic prescription rates were 24% among sites that permitted baseline antipsychotic use in cohort 1 and 18% in the cohort 2; the decline did not quite reach statistical significance (p=0.064). In cohort 2 the mean±SD baseline chlorpromazine-equivalent dose was 121±108mg/d, and lifetime duration of antipsychotic treatment was 3.8±5.9months. DISCUSSION: Although the rate of antipsychotic prescription among high-risk youth may have fallen slightly, the nearly one-in-five rate in the second cohort still constitutes a significant exposure. Mitigating factors were that doses and durations of treatment were low. As for other nonpsychotic conditions, it is incumbent on our field to develop alternative treatments for high-risk patients and to generate additional evidence for or against the efficacy of antipsychotics to help define their appropriate role if alternative treatments fail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.